Actively Recruiting
A Registry Study of Breast Microseed Treatment
Led by Concure Oncology-Breast Microseed Inc. · Updated on 2018-03-19
420
Participants Needed
3
Research Sites
521 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
For women diagnosed with early stage breast cancer, lumpectomy followed by radiation is a common treatment option. Radiation treatment is typically delivered to the whole breast, five times per week, for anywhere from 3 to 8 weeks. The radiation helps kill any cancer cells that may have been left over following the surgery but causes skin burns. Many studies have demonstrated that radiation to the whole breast is not necessary, that it can be delivered to a portion of the breast where the cancer is more likely to recur. A technique called a Permanent Breast Seed Implant (PBSI) involving the implantation of radioactive seeds has been developed to deliver the radiation to a portion of the breast. The procedure is performed on an out-patient basis under local anesthesia and light sedation. Because the radioactive seeds are permanently implanted in the breast, the patient is able to live a normal life while the seeds deliver the prescribed radiation to the breast. Previous studies on PBSI demonstrate that it is a safe and effective alternative form of radiation for appropriately selected patients after lumpectomy. However, those results have been obtained mainly from a single institution, with only 4 patients treated in another center. Further research is still needed to evaluate its safety in a multi-center setting. The purpose of this study is to ensure the appropriate training of clinicians who will be performing this procedure and to capture long term outcomes and rare complications if any.
CONDITIONS
Official Title
A Registry Study of Breast Microseed Treatment
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Histological diagnosis of invasive or in-situ ductal carcinoma (DCIS)
- Treated by breast conserving surgery with axillary node dissection (minimum 6 nodes sampled) or sentinel lymph node biopsy
- Surgical margins clear for invasive carcinoma or at least 2 mm clear for DCIS
- Maximum tumor size of 3 cm
- Age 50 years or older
- Signed informed consent if participating in the Registry
You will not qualify if you...
- Previous cancer unless in remission for more than 2 years
- Active autoimmune disorder with severe vasculitis
- Uncontrolled and complicated insulin-dependent diabetes
- Pregnancy
- Cosmetic breast implants
- Psychiatric or addictive disorder preventing follow-up
- Post-operative breast infection requiring prolonged antibiotics
- Lobular or sarcoma histology
- Node positive on axillary dissection or sentinel lymph node biopsy
- Extensive in-situ carcinoma
- Multicentric disease (more than one quadrant or separated by 2 cm or more)
- Paget's disease of the nipple
- Metastases
- Large post-surgical fluid cavity resistant to hot compresses for 4 weeks
- Unable to clearly define target volume on CT
- Implant volume over 150cc
- Target volume too close to skin causing radiation overlap
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 3 locations
1
Allegheny General Hospital
Pittsburgh, Pennsylvania, United States, 15212
Actively Recruiting
2
Mary Washington Hospital
Fredericksburg, Virginia, United States, 22401
Actively Recruiting
3
Swedish Cancer Institute
Seattle, Washington, United States, 98104
Actively Recruiting
Research Team
J
Juanita Crook, MD
CONTACT
J
Jean-Philippe Pignol, MD, PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here